TRIBE_2 | R Documentation |
Kaplan-Meier digitized data from TRIBE, figure 2 (PMID 26338525). A reported sample size of 508 for a primary endpoint of PFS in colorectal cancer.
TRIBE_2
A data frame of 508 observations and 3 variables:
time | event time (in months) | |
event | OS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (folfiri_bev, folfoxiri_bev) | |
Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015; 16: 1306–15.
summary(TRIBE_2)
kmplot(TRIBE_2)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.